Variant endpoints are employed to capture a broader spectrum of treatment effects. They can be particularly useful in early-phase trials where overall survival might not yet be measurable. By using endpoints such as tumor response rate or biomarker changes, researchers can gain early indications of efficacy and safety, which is critical for making timely decisions about the progression of a clinical trial.